SimLipid informatics platform will be promoted with Waters’ mass spectrometers.

Waters will market Premier Biosoft’s SimLipid® informatics platform, with the goal of augmenting company lipidomics research capabilities. Current offerings include the Acquity UPLC® liquid chromatography system and the high-resolution Synapt® and Xevo® mass spectrometers.

SimLipid is an automatic analysis software that can augment data generated by Waters’ UPLC—HDMSe (ion mobility—mass spectrometry) system by performing an exact mass precursor ion search to generate a list of lipid candidates. Those candidates are then ranked by comparing diagnostic product ions observed in the high energy HDMSe data and structure-specific in silico fragment ions from the SimLipid database.

SimLipid generates portable reports and images in the XLS, CSV, HTML, JPEG, and PNG file formats to facilitate information sharing. Waters says that each structure is mined for its associated class, reaction, pathway, and enzyme to minimize costly and time-consuming manual annotation by scientists.

Waters says its mass spectrometer technology provides greater levels of specificity and class separation to lipid analysis, including the separation of isobaric and isomeric lipid species.

The companies signed a nonexclusive co-marketing and reselling agreement that marks the second accord between the companies in over a year. In May 2010, Waters and Premier Biosoft inked a deal to co-market the SimGlycan® software with Waters mass spectrometry solutions for glycan and glycopeptide analysis. As part of that deal Premier Biosoft agreed to market its software to customers analyzing glycans and glycopeptides on both the Waters Synapt and Xevo mass spec platforms.

Under the new agreement, Waters will continue to sell its UPLC and mass spectrometers for lipid analysis, while Premier Biosoft will market its characterization tool to Waters customers analyzing lipid data.

Previous articleEmergent BioSolutions Continues Expansion into Cancer with mAb Acquisition from TenX
Next articleScientists Boost Antitumor Effects of Dendritic Cell Therapy Using Inflammatory Virus